Table 2.
Clinical characteristics of 2 COVID-19-positive patients
| Patient 1 | Patient 2 | |
|---|---|---|
| Age, years | 69 | 73 |
| Comorbidity | Hypertension* | Hypertension* |
| Diabetes | Hepatitis C positive | |
| Osteoporosis | ||
| Cancer Stage | Stage IV | Stage IV |
| Non-metastatic Castration-resistant PSA: 2 ng/mL (PSA DT: 3 months) |
Metastatic, castration resistant PSA 14 ng/mL Bone metastases |
|
| Cancer treatment | LHRH agonist | LHRH agonist + enzalutamide |
| Concomitant drugs | Insulin | Angiotensin-converting enzyme |
| Calcium channel blockers | inhibitors (ACE) | |
| White blood cell count, µL | ||
| Before | 3,800 | 3,200 |
| Time 0 | 3,200 | 2,900 |
| After 2 weeks | 3,700 | 3,700 |
| Lymphocyte count (% of WBC) | ||
| Before | 35% | 32% |
| Time 0 | 15% | 16% |
| After 2 weeks | 33% | 29% |
| Hemoglobin before | ||
| Time 0 | 11.5 g/dL | 10.4 g/dL |
| After 2 weeks | 11.0 g/dL | 9.4 g/dL |
| 11.4 g/dL | 9.8 g/dL | |
| Platelets, mm3 | ||
| Before | 125.000 | 130.000 |
| Time 0 | 230.000 | 250.000 |
| After 2 weeks | 140.000 | 170.000 |
| C-reactive protein | ||
| Before | Normal | High |
| Time 0 | High | High |
| After 2 weeks | High | High |
| IL-6 | ||
| Time 0 | 2,000 pg/ mL | Unknown |
| After 2 weeks | 160 pg/ mL | |
| Symptoms | Fever: 38.7°C for 1 week | No fever |
| Dyspnea | Dyspnea | |
| Cough | Cough | |
| Duration of hospitalization | 3 weeks | 3 weeks |
| Intubation and invasive mechanical ventilation in ICU | Intubation invasive mechanical ventilation in ICU | |
| Treatment for COVID-19 | Azithromycin | Lopinavir/ritonavir |
| Chloroquine | Chloroquine | |
| Heparin | Heparin | |
| Lopinavir-ritonavir | Extubated | |
| Tocilizumab | ||
| Extubated | ||
| Survival status | Alive | Alive |
Before: 3 weeks before COVID-19 diagnosis. LHRH, luteinizing hormone-releasing hormone; WBC, white blood CELL count; DT: double time.
*
Grade 2 hypertension according to NCI common toxicity criteria for 5 years.